Exhibit 16.1
August 16, 2021
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Commissioners:
We have read the statements made by Indaptus Therapeutics, Inc. (copy attached), which we understand will be filed with the Securities and Exchange Commission, pursuant to Item 4.01 of Form 8-K/A of Indaptus Therapeutics, Inc. dated August 12, 2021. We agree with the statements concerning our Firm contained therein.
Very truly yours,
Tel-Aviv, Israel | /s/ Kesselman & Kesselman |
August 16, 2021 | Certified Public Accountants (Isr.) |
A member firm of PricewaterhouseCoopers International Limited |
Kesselman & Kesselman, 146 Derech Menachem Begin, Tel-Aviv 6492103, Israel,
P.O Box 7187 Tel-Aviv 6107120, Telephone: +972 -3- 7954555, Fax:+972 -3- 7954556, www.pwc.com/il